Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. - Wikidata - awgldk - TriplyDB

Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.

Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.

http://www.wikidata.org/entity/Q34363866

about

Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients Roles for miRNAs in endocrine resistance in breast cancer Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study MicroRNAs in pathogenesis of breast cancer: Implications in diagnosis and treatment.Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1.Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line.Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.Clinical implications of microRNAs in cancer.MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy.Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro.MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer Hypoxia-induced miR-15a promotes mesenchymal ablation and adaptation to hypoxia during lung development in chicken.Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e.Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.miRNAs and estrogen action.CDK4 and miR-15a comprise an abnormal automodulatory feedback loop stimulating the pathogenesis and inducing chemotherapy resistance in nasopharyngeal carcinoma.Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.The role of microRNAs in breast cancer migration, invasion and metastasis Regulation of the Wip1 phosphatase and its effects on the stress response.Current status and implications of microRNAs in ovarian cancer diagnosis and therapy.E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms.New developments in the treatment of HER2-positive breast cancer Therapeutic siRNA for drug-resistant HER2-positive breast cancer.Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review).MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression.miRNA clusters as therapeutic targets for hormone-resistant breast cancer.

P2860

Q22000752-0DAC3762-CE0E-41E8-ABB8-C4D1BE24FCE4 Q26773907-2A0481E7-8114-4A3A-B853-6CD59FCF35A8 Q26782449-C73B6B88-222B-47E2-B82C-F9F7E48E087E Q26783076-5954E563-C7FE-46E2-A65E-F510C346C5DB Q27011221-FAEFF832-E5E3-4A3D-AE30-AC60974CB488 Q28729855-205286C9-AE9B-4A9A-891C-B95F22C330CE Q33585094-8DDA079A-589B-4C19-919F-F9F606B7DEA1 Q33709971-29878C0A-4535-4120-9F05-19C6E12D712A Q33729914-AE05465B-777C-476E-90BC-F27F4D80D889 Q33850064-006EFAFD-424B-404F-BE69-54AC83459737 Q34504974-B462192C-0CA6-47FA-AB57-796BDEACAA07 Q34506613-C932E6BF-24C7-45BE-9D6D-D8E6EF02B1A0 Q34539750-F28DBFAC-4D50-4EEE-B1F2-8CCF51CDDDD9 Q34570698-6CE94A6D-E000-4B07-B49D-93520046D24A Q34756694-2F00EF16-577A-4B1A-9B38-BB0CE0CA576D Q35039281-CCAFB0FC-0170-41EC-8EC8-28966B5B52D5 Q35108358-85707615-0F95-4E4B-BDF9-05A8DE33C2F0 Q35128098-942924AF-B2A3-4531-BB0C-F0D883DCED08 Q35179724-6B52292C-43D4-4285-BADF-29237A04A9BA Q35562595-7AA138EC-224A-41A2-A1C8-80B0AFCA65FB Q35599629-261D3E01-AF27-4782-8BF5-24DCB37224D2 Q35709636-2D6AC5AC-5659-4C08-9210-D56EA528BB51 Q35906736-B839FB53-0550-48A7-AEEF-0EBCB2B69F93 Q35946984-CEBA6582-9896-4833-A2FE-DD473A686482 Q35963331-D4DD5264-B25A-4627-B8AB-9B8142627700 Q36067934-D619D0CD-A532-4A87-8A21-6EFA4FC7A5D0 Q36107033-99A0209B-0941-4480-90F2-81F45CB973C8 Q36396579-E239E715-88EC-415E-9292-14954883131D Q36429982-4FD1B410-F1B1-48FB-90A5-FA11637A18A1 Q36517492-CFB3D867-CB27-4F49-9BD1-F504B9CF7939 Q36544743-9730D2CE-9D0C-4FEB-8FCC-56E4FCA2E052 Q36589865-1B225E1D-A72F-40BA-8DAF-F9461F88789B Q36846329-FEFC4668-6351-4E0B-B60E-2FD3F96D6C39 Q37016382-7F4CBA19-35D1-41EA-9C43-3E366F135A58 Q37046699-652DE2B8-FCC3-469F-BEE4-25F781DC1105 Q37092904-CE7D76E2-CC5D-45CF-AF50-D55774F14034 Q37109741-F9C2B5DC-6066-43C1-8759-19002BC156F0 Q37211627-A0048C5A-61FA-4194-A3DC-3BF71885B9F8 Q37269100-B236FDAD-E507-4D1F-86AE-F5E35364A631 Q37316805-0A5167DC-AD2B-4530-940A-82158F59DD9E

P2860

Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.

http://www.wikidata.org/entity/Q34363866

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.

@ast

Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.

@en

Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.

@nl

type

label

Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.

@ast

Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.

@en

Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.

@nl

prefLabel

Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.

@ast

Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.

@en

Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.

@nl

P1433

Q34363866-D027E46A-CDBA-4DD4-840F-D147F1038010

P1476

Q34363866-F0E67B36-DFC2-45B0-86C0-663EC047A2A0

P2093

Q34363866-364AAD4B-B80B-43B9-BF8F-4EE940E7C98B

Q34363866-3E45D295-0EAE-4314-A624-C75B1938884A

Q34363866-7E4DDA1E-1594-4AF4-A138-D619D22D5CE2

Q34363866-82097F86-0FC4-4517-9242-A48D31091D20

Q34363866-92F78299-F1BC-419F-AE09-76F7C234EC69

Q34363866-A7C7B8E0-6EE3-442B-8615-43E4A3B97CCB

P2860

Q34363866-01246354-5833-4569-A060-E4070CBFDDA2

Q34363866-06EAAA13-CA97-4DE4-B929-8135F17F02F5

Q34363866-09BB4141-B0EC-478E-9574-1357515DA68B

Q34363866-0A1DE452-6D3A-4CF0-95FE-75FA25F58798

Q34363866-0C331F5F-D339-409A-8D85-838D5B1F0EC0

Q34363866-25E980F8-8313-4F3C-B774-000B64D35B43

Q34363866-2A8C99D8-112C-4771-9A38-58084EA57D0E

Q34363866-3578852D-B8B8-4524-AC46-B1E7F71CF396

Q34363866-41141BC0-BBAA-4698-AFFD-CD6F7711055D

Q34363866-460A0B32-A619-4106-B9ED-18A4E4B79D5F

P304

Q34363866-741558C1-56EA-4FB3-BBA8-B0C9258676F3

P31

Q34363866-EEE854F3-553C-48C7-879E-07E81D831EE3

P356

Q34363866-5051166C-9A2C-4202-8C9A-976A99E1A7B9

P407

Q34363866-B9A141AC-2ECC-4B0A-AD15-93F943646C77

P433

Q34363866-395FC99E-DE04-4861-8502-76EE8852081A

P478

Q34363866-863005CB-7321-4D57-84BE-86E4F688F036

P577

Q34363866-B9E1A44D-A449-425E-9A84-932DB4C0700F

P5875

Q34363866-6BAFF603-D978-4D3B-8E16-513F8512DDD9

P698

Q34363866-6814554D-6064-4D66-A32D-6AF7828665A2

P932

Q34363866-0ADAC54F-3F06-46C2-96B6-E6819118512C

P356

P1433

P1476

Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.

@en

P2093

Diana M Cittelly

http://www.w3.org/2001/XMLSchema#string

Frank E Jones

http://www.w3.org/2001/XMLSchema#string

Juan P Fonseca

http://www.w3.org/2001/XMLSchema#string

Matthew E Burow

http://www.w3.org/2001/XMLSchema#string

Partha M Das

http://www.w3.org/2001/XMLSchema#string

Virgilio A Salvo

http://www.w3.org/2001/XMLSchema#string

P2860

The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents

miR-15 and miR-16 induce apoptosis by targeting BCL2

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy

MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer

MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1

Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells

Oncomirs - microRNAs with a role in cancer

miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

P304

2049-2057

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CARCIN/BGQ192

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46578470

http://www.w3.org/2001/XMLSchema#string

P698

20876285

http://www.w3.org/2001/XMLSchema#string

P932

2994280

http://www.w3.org/2001/XMLSchema#string